508 related articles for article (PubMed ID: 22476471)
1. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
[TBL] [Abstract][Full Text] [Related]
2. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
3. Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
Samama CM; Rosencher N; Kleine E; Feuring M; Brueckmann M; Clemens A; Gullberg J; Frostick SP
Thromb Res; 2016 Jul; 143():103-10. PubMed ID: 27208980
[TBL] [Abstract][Full Text] [Related]
4. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
Eriksson BI; Lassen MR;
Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.
Penning-van Beest FJ; Overbeek JA; Meijer WM; Woodruff K; Jackson J; van der Vis H; van der Linden P; Herings RM
Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):972-8. PubMed ID: 21748826
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients.
Turpie AG; Lensing AW; Fuji T; Boyle DA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):114-21. PubMed ID: 19339838
[TBL] [Abstract][Full Text] [Related]
7. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
10. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study.
Silvestri F; Pasca S; Labombarda A; Barbi A; Desideri M; Guidi P; Rogato A; Zaramella M; Bergamo M; Ageno W; Barillari G
Minerva Med; 2014 Jun; 105(3):221-8. PubMed ID: 24988087
[TBL] [Abstract][Full Text] [Related]
11. [Prophylaxis of venous thromboembolism in orthopedic surgery].
Giuseppini MU; Guiducci S; Bardelli M
Minerva Med; 2010 Feb; 101(1):49-58. PubMed ID: 20228720
[TBL] [Abstract][Full Text] [Related]
12. Assessing the quality of pharmacological treatments from administrative databases: the case of low-molecular-weight heparin after major orthopaedic surgery.
Gerkens S; Beguin C; Crott R; Closon MC; Horsmans Y
J Eval Clin Pract; 2008 Aug; 14(4):585-94. PubMed ID: 18462276
[TBL] [Abstract][Full Text] [Related]
13. Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.
Selby R; Borah BJ; McDonald HP; Henk HJ; Crowther M; Wells PS
Thromb Res; 2012 Aug; 130(2):166-72. PubMed ID: 22365491
[TBL] [Abstract][Full Text] [Related]
14. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients.
Fuji T; Fujita S; Ochi T
Int Orthop; 2008 Aug; 32(4):443-51. PubMed ID: 17468868
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice.
Delavenne X; Zufferey P; Baylot D; Nguyen P; Borg JY; Fontenay M; Deygas B; Mismetti P; Laporte S; ;
Thromb Haemost; 2010 Aug; 104(2):252-60. PubMed ID: 20539905
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
17. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
[TBL] [Abstract][Full Text] [Related]
18. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials.
Eikelboom JW; Quinlan DJ; O'Donnell M
Circulation; 2009 Nov; 120(20):2006-11. PubMed ID: 19884469
[TBL] [Abstract][Full Text] [Related]
19. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
20. Clinical venous thromboembolism following joint surgery: effect of extended thromboprophylaxis on its annual frequency and postoperative pattern over 22 years.
Dahl OE; Gudmundsen TE; Pripp AH; Aanesen JJ
Clin Appl Thromb Hemost; 2014 Mar; 20(2):117-23. PubMed ID: 24113492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
